First Phase 3 OS Results With Melanoma ImmunoTx Combo First Phase 3 OS Results With Melanoma ImmunoTx Combo

Nivolumab, alone or in combination with ipilimumab, was better than ipilimumab monotherapy in a phase 3 trial. But there ' s another pressing question with this first-of-its-kind clinical trial.Medscape Medical News
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news